Dr. Mark Kris highlights the therapeutic benefits -- and toxicities -- associated with bevacizumab use in patients with non-small cell lung cancer. Medscape Hematology-Oncology
The novel small molecule navitoclax blocks the function of Bcl-2, a protein essential for the growth of chronic lymphocytic leukemia cells, and may represent a "revolution" in the treatment of CLL. Medscape Medical News
In this Expert Interview from ASCO 2008, Dr. Robert Motzer discusses the evolving role of mTOR inhibition in the treatment of renal cell carcinoma, with a focus on the newest agent in the class. Medscape Hematology-Oncology